secwatch.observer — SEC 8-K summary
======================================

Issuer:     TENAX THERAPEUTICS, INC. (TENX)
CIK:        0000034956
Form:       8-K
Filed at:   2023-01-04T23:59:59+00:00
Accession:  0001654954-23-000110
Event type: other_material
Sentiment:  negative
Materiality: 0.50
Item codes: 3.03, 5.03, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Tenax Therapeutics effects 1-for-20 reverse stock split to meet Nasdaq minimum bid price
--------------------------------------------------------------------------------

- Reverse stock split at 1-for-20 ratio effective 5:00 p.m. ET on January 4, 2023.
- Shares outstanding reduced from 45,836,215 to approximately 2,291,811; no fractional shares issued, rounded up.
- Stock to trade split-adjusted on Nasdaq under symbol TENX starting January 5, 2023; new CUSIP 88032L506.
- Reverse split was approved by shareholders on June 9, 2022; board set ratio on December 15, 2022.
- Purpose is to regain compliance with Nasdaq's minimum $1.00 bid price requirement for continued listing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/34956/000165495423000110/0001654954-23-000110-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/34956/000165495423000110/tenx_8k.htm
  HTML page:      https://secwatch.observer/filing/0001654954-23-000110

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer